Skip to main content
Premium Trial:

Request an Annual Quote

Precision Antibody Completes SBIR Contract to Generate Antibodies for SISCAPA Assays


NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.

Under the contract, Precision generated an unspecific number of new mouse monoclonal antibodies for use in SISCAPA mass spec assays.

SISCAPA uses antibody-based capture of target peptides prior to mass spec analysis to increase the sensitivity and throughput of traditional selected-reaction monitoring assays. As such, a catalogue of high-quality antibodies to peptide targets is key to the technology's utility.

Precision generated the antibodies using its proprietary Affinity Boost, SMART Fusion, and SeleKDt technologies, which, it said, enabled antibodies with higher affinity and lower off-rates than typical mouse monoclonals.